Lumos Pharma (LUMO) Short Interest Ratio & Short Volume

Short interest is the volume of Lumos Pharma shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 297,500 shares of LUMO short. 5.74% of Lumos Pharma's shares are currently sold short. Learn More on Lumos Pharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LUMO shares currently have a short interest ratio of 10.0. Learn More on Lumos Pharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.74% of Lumos Pharma's floating shares are currently sold short.

Lumos Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 297,500 shares, a decrease of 0.9% from the previous total of 300,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Lumos Pharma currently has issued a total of 8,120,000 shares. Some of Lumos Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lumos Pharma currently has a public float of 5,180,000 shares.

5.74% of Lumos Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Lumos Pharma: MEI Pharma, Inc. (0.50%), Indaptus Therapeutics, Inc. (0.28%), Aptorum Group Limited (0.40%), Forte Biosciences, Inc. (0.07%), Cocrystal Pharma, Inc. (0.09%), Synlogic, Inc. (1.13%), BioVie Inc. (1.79%), VBI Vaccines Inc. (1.18%), Sol-Gel Technologies Ltd. (0.11%), CytoMed Therapeutics Limited (0.97%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling LUMO is an investing strategy that aims to generate trading profit from Lumos Pharma as its price is falling. LUMO shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lumos Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LUMO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LUMO, twice per month. The most recent reporting period available is May, 15 2024.